Navigation Links
Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
Date:7/31/2008

SEATTLE, July 31 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for second quarter and first six months ended June 30, 2008, after the close of market on Aug. 7, 2008. The company's earnings conference call will take place Aug. 7, 2008, at 2 p.m. PDT (5 p.m. EDT).

Both live events will be available for viewing on Trubion's website at http://investors.trubion.com/events.cfm.

Second Quarter and First Six Months Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, Aug. 7, 2008

Trubion will host a conference call and webcast to discuss its second quarter and six months 2008 financial results. The call will be held Aug. 7 at 2 p.m. Pacific time (5 p.m. Eastern time). The live event will be available from Trubion's website at http://investors.trubion.com/events.cfm, or by calling 1 (719) 325-4916 or 1 (877) 397-0292. A replay of the discussion will be available from Trubion's website or by calling 1 (719) 457-0820 or 1 (888) 203-1112 and entering 6969493. Replay will be available at 8 p.m. EDT until midnight, Aug. 14, 2008. The webcast replay will be available in the events section of Trubion's website.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Trubion Announces Presentations at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... (PRWEB) , ... January 14, 2017 , ... AgileMinder develops ... , The Emoji Scale is now available on Apple as a fun, free ... ratings simply by choosing one of the ten color coded values on The Emoji ...
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: Perspectives in Lung ... 3-4, 2017. This Congress is expertly designed to meet the educational needs of ... lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of Oncology at the ...
(Date:1/13/2017)... ... ... With the increasing public preference for chemical-free personal care ... for customers who have grown more conscious about maintaining their health and wellness. ... products, Moody Zook Chief Executive Officer Nate Ginsburg explained their company’s decision to ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are about ... they brush their teeth. Sadly, most dental hygiene products in the market contain chemical ... For these people, continuing their daily oral care routine to keep their teeth white ...
(Date:1/13/2017)... ... January 13, 2017 , ... On ... Finnleo factory in Cokato, MN, with the official send-off from Orchestra Hall in ... Osmo Vanska , Minnesota Orchestra’s Music Director, leading the official launch of the ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), today ... and Investment Banking at Eli Lilly & Company, has been ... brings over 28 years of senior financial and executive leadership ... ... established a significant leadership position in financial and business expertise ...
(Date:1/13/2017)... Calif. , Jan. 13, 2017  Alfalfa, cattle, leafy ... Diagnostic,s new environmental sampling film , which emphasizes the food ... released today, highlights how COPAN,s Swab ... that simplifies the surface sampling process in the wake of ... In addition, COPAN is expanding the ...
(Date:1/13/2017)... 2017  Secretary of Health Karen Murphy ... members at Misericordia University and discussed the Wolf Administration,s ... Pennsylvania . "The opioid epidemic is ... in my professional career," Secretary Murphy said. "This area ... hard by heroin and prescription opioid overdoses. Across the ...
Breaking Medicine Technology: